Morpholino

MO4-ep300a

ID
ZDB-MRPHLNO-180709-2
Name
MO4-ep300a
Previous Names
None
Target
Sequence
5' - TATTTATACACTCACCTTGGCAGGA - 3'
ZFIN BLAST NCBI BLAST Ensembl UCSC BLAT
Disclaimer
Although ZFIN verifies reagent sequence data, we recommend that you conduct independent sequence analysis before ordering any reagent.
Note
Splice-blocking MO.
Genome Resources
None
Target Location
Genomic Features
No data available
Expression
Gene expression in Wild Types + MO4-ep300a
Expressed Gene Anatomy Figures
foxd3 Fig. 6 from Babu et al., 2018
mbpa Fig. 6 from Babu et al., 2018
neurod1 Fig. 6 from Babu et al., 2018
sox9a Fig. 5 from Babu et al., 2018
sox9b Fig. 5 from Babu et al., 2018
tbx5a Fig. 5 from Babu et al., 2018
Phenotype
Phenotype resulting from MO4-ep300a
Phenotype Fish Figures
atrium increased size, abnormal gib1002Tg + MO4-ep300a Fig. 4 from Babu et al., 2018
cartilage tissue sox9b expression decreased amount, abnormal TU + MO4-ep300a Fig. 5 from Babu et al., 2018
cranial ganglion neurod1 expression absent, abnormal TU + MO4-ep300a Fig. 6 from Babu et al., 2018
cranial skeletal system development disrupted, abnormal gib1002Tg + MO4-ep300a Fig. 4 from Babu et al., 2018
glial cell mbpa expression decreased amount, abnormal TU + MO4-ep300a Fig. 6 from Babu et al., 2018
hindbrain neurod1 expression decreased amount, abnormal TU + MO4-ep300a Fig. 6 from Babu et al., 2018
pectoral fin aplastic/hypoplastic, abnormal gib1002Tg + MO4-ep300a Fig. 4 from Babu et al., 2018
pectoral fin tbx5a expression decreased amount, abnormal TU + MO4-ep300a Fig. 5 from Babu et al., 2018
pectoral fin cartilage sox9b expression decreased amount, abnormal TU + MO4-ep300a Fig. 5 from Babu et al., 2018
pectoral fin cartilage sox9a expression decreased amount, abnormal TU + MO4-ep300a Fig. 5 from Babu et al., 2018
pericardium edematous, abnormal gib1002Tg + MO4-ep300a Fig. 4 from Babu et al., 2018
peripheral olfactory organ neurod1 expression absent, abnormal TU + MO4-ep300a Fig. 6 from Babu et al., 2018
pharyngeal arch 1 decreased size, abnormal gib1002Tg + MO4-ep300a Fig. 4 from Babu et al., 2018
pharyngeal arch 2 decreased size, abnormal gib1002Tg + MO4-ep300a Fig. 4 from Babu et al., 2018
pharyngeal arch 3-7 decreased size, abnormal gib1002Tg + MO4-ep300a Fig. 4 from Babu et al., 2018
retina neurod1 expression absent, abnormal TU + MO4-ep300a Fig. 6 from Babu et al., 2018
statoacoustic (VIII) ganglion neurod1 expression decreased amount, abnormal TU + MO4-ep300a Fig. 6 from Babu et al., 2018
whole organism has fewer parts of type pectoral fin, abnormal gib1002Tg + MO4-ep300a Fig. 4 from Babu et al., 2018
Phenotype of all Fish created by or utilizing MO4-ep300a
Phenotype Fish Conditions Figures
statoacoustic (VIII) ganglion neurod1 expression decreased amount, abnormal TU + MO4-ep300a control Fig. 6 from Babu et al., 2018
cartilage tissue sox9b expression decreased amount, abnormal TU + MO4-ep300a standard conditions Fig. 5 from Babu et al., 2018
cranial ganglion neurod1 expression absent, abnormal TU + MO4-ep300a control Fig. 6 from Babu et al., 2018
pectoral fin cartilage sox9b expression decreased amount, abnormal TU + MO4-ep300a standard conditions Fig. 5 from Babu et al., 2018
peripheral olfactory organ neurod1 expression absent, abnormal TU + MO4-ep300a control Fig. 6 from Babu et al., 2018
hindbrain neurod1 expression decreased amount, abnormal TU + MO4-ep300a control Fig. 6 from Babu et al., 2018
pectoral fin cartilage sox9a expression decreased amount, abnormal TU + MO4-ep300a standard conditions Fig. 5 from Babu et al., 2018
retina neurod1 expression absent, abnormal TU + MO4-ep300a control Fig. 6 from Babu et al., 2018
pectoral fin tbx5a expression decreased amount, abnormal TU + MO4-ep300a control Fig. 5 from Babu et al., 2018
glial cell mbpa expression decreased amount, abnormal TU + MO4-ep300a control Fig. 6 from Babu et al., 2018
pectoral fin aplastic/hypoplastic, abnormal gib1002Tg + MO4-ep300a standard conditions Fig. 4 from Babu et al., 2018
whole organism has fewer parts of type pectoral fin, abnormal gib1002Tg + MO4-ep300a standard conditions Fig. 4 from Babu et al., 2018
cranial skeletal system development disrupted, abnormal gib1002Tg + MO4-ep300a standard conditions Fig. 4 from Babu et al., 2018
atrium increased size, abnormal gib1002Tg + MO4-ep300a standard conditions Fig. 4 from Babu et al., 2018
pharyngeal arch 2 decreased size, abnormal gib1002Tg + MO4-ep300a standard conditions Fig. 4 from Babu et al., 2018
pericardium edematous, abnormal gib1002Tg + MO4-ep300a standard conditions Fig. 4 from Babu et al., 2018
pharyngeal arch 3-7 decreased size, abnormal gib1002Tg + MO4-ep300a standard conditions Fig. 4 from Babu et al., 2018
pharyngeal arch 1 decreased size, abnormal gib1002Tg + MO4-ep300a standard conditions Fig. 4 from Babu et al., 2018
trunk glioblast foxd3 expression increased amount, abnormal TU + MO3-ep300b + MO4-ep300a control Fig. 6 from Babu et al., 2018
statoacoustic (VIII) ganglion neurod1 expression decreased amount, abnormal TU + MO3-ep300b + MO4-ep300a control Fig. 6 from Babu et al., 2018
cartilage tissue sox9b expression decreased amount, abnormal TU + MO3-ep300b + MO4-ep300a standard conditions Fig. 5 from Babu et al., 2018
cranial ganglion neurod1 expression absent, abnormal TU + MO3-ep300b + MO4-ep300a control Fig. 6 from Babu et al., 2018
pectoral fin cartilage sox9b expression decreased amount, abnormal TU + MO3-ep300b + MO4-ep300a standard conditions Fig. 5 from Babu et al., 2018
peripheral olfactory organ neurod1 expression absent, abnormal TU + MO3-ep300b + MO4-ep300a control Fig. 6 from Babu et al., 2018
hindbrain neurod1 expression decreased amount, abnormal TU + MO3-ep300b + MO4-ep300a control Fig. 6 from Babu et al., 2018
pectoral fin cartilage sox9a expression decreased amount, abnormal TU + MO3-ep300b + MO4-ep300a standard conditions Fig. 5 from Babu et al., 2018
retina neurod1 expression absent, abnormal TU + MO3-ep300b + MO4-ep300a control Fig. 6 from Babu et al., 2018
head glioblast foxd3 expression increased amount, abnormal TU + MO3-ep300b + MO4-ep300a control Fig. 6 from Babu et al., 2018
pectoral fin tbx5a expression decreased amount, abnormal TU + MO3-ep300b + MO4-ep300a control Fig. 5 from Babu et al., 2018
glial cell mbpa expression decreased amount, abnormal TU + MO3-ep300b + MO4-ep300a control Fig. 6 from Babu et al., 2018
cranial skeletal system development disrupted, ameliorated gib1002Tg + MO3-ep300b + MO4-ep300a chemical treatment: 4-(dimethylamino)-N-[7-(hydroxyamino)-7-oxoheptyl]benzamide Fig. 8 from Babu et al., 2018
pharyngeal arch 3-7 aplastic/hypoplastic, abnormal gib1002Tg + MO3-ep300b + MO4-ep300a control Fig. 8 from Babu et al., 2018
cranial skeletal system development disrupted, ameliorated gib1002Tg + MO3-ep300b + MO4-ep300a chemical treatment: EC 3.5.1.98 (histone deacetylase) inhibitor Fig. 8 from Babu et al., 2018
atrium position, abnormal gib1002Tg + MO3-ep300b + MO4-ep300a standard conditions Fig. 4 from Babu et al., 2018
pharyngeal arch 2 decreased size, abnormal gib1002Tg + MO3-ep300b + MO4-ep300a standard conditions Fig. 4,  Fig. 8 from Babu et al., 2018
pericardium edematous, abnormal gib1002Tg + MO3-ep300b + MO4-ep300a standard conditions Fig. 4 from Babu et al., 2018
pharyngeal arch 1 decreased size, abnormal gib1002Tg + MO3-ep300b + MO4-ep300a standard conditions Fig. 4,  Fig. 8 from Babu et al., 2018
cardiac ventricle position, abnormal gib1002Tg + MO3-ep300b + MO4-ep300a standard conditions Fig. 4 from Babu et al., 2018
cartilage tissue sox9b expression amount, ameliorated gib1002Tg + MO3-ep300b + MO4-ep300a chemical treatment: 4-(dimethylamino)-N-[7-(hydroxyamino)-7-oxoheptyl]benzamide Fig. 8 from Babu et al., 2018
cranial skeletal system development disrupted, abnormal gib1002Tg + MO3-ep300b + MO4-ep300a standard conditions Fig. 4,  Fig. 8 from Babu et al., 2018
pharyngeal arch 2 decreased size, ameliorated gib1002Tg + MO3-ep300b + MO4-ep300a chemical treatment: EC 3.5.1.98 (histone deacetylase) inhibitor Fig. 8 from Babu et al., 2018
pharyngeal arch 3-7 aplastic/hypoplastic, ameliorated gib1002Tg + MO3-ep300b + MO4-ep300a chemical treatment: EC 3.5.1.98 (histone deacetylase) inhibitor Fig. 8 from Babu et al., 2018
pectoral fin aplastic/hypoplastic, abnormal gib1002Tg + MO3-ep300b + MO4-ep300a standard conditions Fig. 4,  Fig. 8 from Babu et al., 2018
pectoral fin aplastic/hypoplastic, ameliorated gib1002Tg + MO3-ep300b + MO4-ep300a chemical treatment: 4-(dimethylamino)-N-[7-(hydroxyamino)-7-oxoheptyl]benzamide Fig. 8 from Babu et al., 2018
pectoral fin development disrupted, abnormal gib1002Tg + MO3-ep300b + MO4-ep300a control Fig. 8 from Babu et al., 2018
pectoral fin aplastic/hypoplastic, ameliorated gib1002Tg + MO3-ep300b + MO4-ep300a chemical treatment: EC 3.5.1.98 (histone deacetylase) inhibitor Fig. 8 from Babu et al., 2018
pharyngeal arch 1 decreased size, ameliorated gib1002Tg + MO3-ep300b + MO4-ep300a chemical treatment: 4-(dimethylamino)-N-[7-(hydroxyamino)-7-oxoheptyl]benzamide Fig. 8 from Babu et al., 2018
pectoral fin development disrupted, ameliorated gib1002Tg + MO3-ep300b + MO4-ep300a chemical treatment: EC 3.5.1.98 (histone deacetylase) inhibitor Fig. 8 from Babu et al., 2018
pharyngeal arch 1 decreased size, ameliorated gib1002Tg + MO3-ep300b + MO4-ep300a chemical treatment: EC 3.5.1.98 (histone deacetylase) inhibitor Fig. 8 from Babu et al., 2018
whole organism has fewer parts of type pectoral fin, abnormal gib1002Tg + MO3-ep300b + MO4-ep300a standard conditions Fig. 4 from Babu et al., 2018
pectoral fin development disrupted, ameliorated gib1002Tg + MO3-ep300b + MO4-ep300a chemical treatment: 4-(dimethylamino)-N-[7-(hydroxyamino)-7-oxoheptyl]benzamide Fig. 8 from Babu et al., 2018
eye decreased size, abnormal gib1002Tg + MO3-ep300b + MO4-ep300a standard conditions Fig. 4 from Babu et al., 2018
cartilage tissue sox9b expression amount, ameliorated gib1002Tg + MO3-ep300b + MO4-ep300a chemical treatment: EC 3.5.1.98 (histone deacetylase) inhibitor Fig. 8 from Babu et al., 2018
cartilage tissue sox9b expression decreased amount, abnormal gib1002Tg + MO3-ep300b + MO4-ep300a control Fig. 8 from Babu et al., 2018
pharyngeal arch 2 decreased size, ameliorated gib1002Tg + MO3-ep300b + MO4-ep300a chemical treatment: 4-(dimethylamino)-N-[7-(hydroxyamino)-7-oxoheptyl]benzamide Fig. 8 from Babu et al., 2018
atrium increased size, abnormal gib1002Tg + MO3-ep300b + MO4-ep300a standard conditions Fig. 4 from Babu et al., 2018
pharyngeal arch 3-7 aplastic/hypoplastic, ameliorated gib1002Tg + MO3-ep300b + MO4-ep300a chemical treatment: 4-(dimethylamino)-N-[7-(hydroxyamino)-7-oxoheptyl]benzamide Fig. 8 from Babu et al., 2018
pharyngeal arch 3-7 decreased size, abnormal gib1002Tg + MO3-ep300b + MO4-ep300a standard conditions Fig. 4 from Babu et al., 2018
heart looping disrupted, abnormal gib1002Tg + MO3-ep300b + MO4-ep300a standard conditions Fig. 4 from Babu et al., 2018
Citations
Your Input Welcome
We welcome your input and comments. Please use this form to recommend updates to the information in ZFIN. We appreciate as much detail as possible and references as appropriate. We will review your comments promptly.
Please check the highlighted fields and try again.
Thank you for submitting comments. Your input has been emailed to ZFIN curators who may contact you if additional information is required.
Oops. Something went wrong. Please try again later.